Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Dimerix Limited
  6. News
  7. Summary
    DXB   AU000000DXB7

DIMERIX LIMITED

(DXB)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Dimerix : Secures Ethics, Regulatory Approval for Phase 3 Kidney Disease Trial in Australia

10/21/2021 | 01:46am EST


ę MT Newswires 2021
All news about DIMERIX LIMITED
01/10Dimerix Doses First Patients in Phase 3 Study of COVID-19 Respiratory Complications Dru..
MT
01/10Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India
CI
2021Dimerix Secures Australian Ethics Approval for Phase 3 Study of COVID-19 Drug Candidate..
MT
2021Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study
CI
2021Dimerix Secures Further Grant Funding for COVID-19 Drug Candidate
MT
2021Dimerix Limited Announces It Has Been Awarded Further AUD 100,000 from the Australian G..
CI
2021Dimerix Limited Advises That 662 Patients Have Now Been Recruited into the Feasibility/..
CI
2021DIMERIX : Notification regarding unquoted securities - DXB
PU
2021DIMERIX : Secures Ethics, Regulatory Approval for Phase 3 Kidney Disease Trial in Australi..
MT
2021Dimerix Limited Announces First Approvals Received for Start of Phase 3 FSGS Trial
CI
More news
Financials
Sales 2021 4,44 M 3,18 M 3,18 M
Net income 2021 -6,37 M -4,56 M -4,56 M
Net cash 2021 0,16 M 0,11 M 0,11 M
P/E ratio 2021 -6,06x
Yield 2021 -
Capitalization 75,4 M 54,0 M 54,0 M
EV / Sales 2020 26,7x
EV / Sales 2021 8,66x
Nbr of Employees -
Free-Float -
Chart DIMERIX LIMITED
Duration : Period :
Dimerix Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DIMERIX LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Nina Webster Chief Executive Officer, MD & Director
Hamish George Chief Financial Officer & Secretary
James Howard Williams Non-Executive Chairman
David Packham Chief Medical Officer
Robert Shepherd Director-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
DIMERIX LIMITED-4.08%54
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381